Advertisement

Wiener klinische Wochenschrift

, Volume 131, Issue 19–20, pp 493–501 | Cite as

Association of sprue-like enteropathy and angiotensin receptor-1 antagonists

  • René R. WenzelEmail author
  • Christian Datz
review article
  • 134 Downloads

Summary

Over the past 5 years several case reports and cohort studies have been published that describe a sprue-like enteropathy (SLE) with abdominal pain, chronic diarrhea and weight loss, after taking angiotensin type 1 receptor blockers (ARB). The initial case series from the Mayo Clinic, which described 22 cases of olmesartan-induced SLE, was followed by numerous case descriptions for almost all ARBs. A total of 73 case reports have been described so far that show evidence of ARB-associated enteropathy with villous atrophy and full recovery 3–12 months after discontinuation of the sartan in question. Of these, 59 cases were olmesartan-associated cases of SLE, another 14 case reports have been published for telmisartan (4), valsartan (3), losartan (2), candesartan (1) and eprosartan (1). Based on the available cohort studies, ARB-associated intestinal malabsorption occurs in 9.8–14 cases per 100,000 patients treated with ARBs, the number treated to harm is over 31,000 patient-years. Although the majority of case reports have been published with olmesartan, in the cohort studies no clear difference within the ARBs can be ruled out. The SLE is rare but must be suspected and diagnostically investigated in every patient presenting with abdominal discomfort, chronic diarrhea and weight loss who is being treated with an ARB, after other causes have been ruled out. In such cases, discontinuing the ARB leads to a full recovery.

Keywords

Malabsorption Hypertension Renin-Angiotensin-System Diarrhea AT1-receptor-antagonist 

Abbreviations

α1

Alpha-1-adrenoceptor

ARB

Angiotensin receptor‑1 antagonist

AT1

Angiotension-receptor‑1

AT2

Angiotension-receptor‑2

CL−

Chloride

ECV

Extracellular fluid volume

K+

Potassium

NA+

Sodium

PG

Prostaglandins

SLE

Sprue-like enteropathy

TGF beta

Transforming growth factor beta

TNF-alpha

Tumor necrosis factor alpha

Notes

Conflict of interest

R.R. Wenzel: For the following companies there is a conflict of interest with the presented data due to consultancy fees or sponsoring: Actelion, Astra-Zeneca, Abbott, Bayer, Daichii-Sankyo, Gepamed, Medtronic, Menarini, Novartis, Speedel Pharma, St Jude Medical and Takeda. C. Datz declares that he has no competing interests.

References

  1. 1.
    Freeman HJ. Drug-induced Sprue-like intestinal disease. Int J Celiac Dis. 2014;2:49–53.CrossRefGoogle Scholar
  2. 2.
    Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Olmesartan-induced Enteropathy. Methodist Debakey Cardiovasc J. 2016;12:230–2.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Scialom S, Malamut G, Meresse B, et al. Gastrointestinal disorder associated with Olmesartan mimics Autoimmune Enteropathy. PLoS ONE. 2015;10:e125024.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fiorucci G, Puxeddu E, Colella R, Reboldi PG, Villanacci V, Bassotti G. Severe spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig. 2014;106:142–4.CrossRefPubMedGoogle Scholar
  7. 7.
    DeGaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647–53.CrossRefPubMedGoogle Scholar
  8. 8.
    Dreifuss SE, Tomizawa Y, Farber NJ, Davison JM, Sohnen AE. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013;2013:1–3.Google Scholar
  9. 9.
    Fabian E, Schiller D, Wenzl H, et al. Clinical-Pathological Conference Series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20 kilograms. Wien Klin Wochenschr. 2015;127:974–80.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016;65:1664–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Mondet L, Pierson-Marchandise M, Gras V, et al. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! A case report with candesartan. Fundam Clin Pharmacol. 2016;30:62.Google Scholar
  13. 13.
    Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015;51:87–8.PubMedGoogle Scholar
  14. 14.
    Cammarota G, Ianiro G, Bibbo S, Letter GA. telmisartan associated enteropathy—is there any class effect? Authors’ reply. Aliment Pharmacol Ther. 2014;40:570.CrossRefPubMedGoogle Scholar
  15. 15.
    Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe Sprue-like Enteropathy associated with Losartan. J Clin Gastroenterol. 2015;49:794.CrossRefPubMedGoogle Scholar
  16. 16.
    Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe Sprue-like Enteropathy associated with Valsartan. Acg Case Rep J. 2015;2:92–4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sawant AP, Spoletini G, Etherington C. Losartan-associated spruelike enteropathy in a post-lung transplant cystic fibrosis patient. J Cyst Fibros. 2017;16:135.CrossRefGoogle Scholar
  18. 18.
    Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy—is there any class effect? Aliment Pharmacol Ther. 2014;40:569–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Mandavdhare HS, Sharma V, Prasad KK, Kumar A, Rathi M, Rana SS. Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. Intest Res. 2017;15:419–21.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    De Bortoli N, Ripellino C, Cataldo N, Marchi S. Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings. Expert Opin Drug Saf. 2017;16:1221–5.  https://doi.org/10.1080/14740338.2017.1376647.CrossRefPubMedGoogle Scholar
  21. 21.
    Malfertheiner P, Ripellino C, Cataldo N. Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. Pharmacoepidemiol Drug Saf. 2018;27(6):581–586.  https://doi.org/10.1002/pds.4402 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    You SC, Park H, Yoon D, Park S, Joung B, Park RW. Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study. Korean J Intern Med. 2019;34(1):90-98.  https://doi.org/10.3904/kjim.2017.002 CrossRefPubMedGoogle Scholar
  23. 23.
    Levens NR. Control of intestinal absorption by the renin-angiotensin system. Am J Physiol. 1985;249:G3–15.CrossRefPubMedGoogle Scholar
  24. 24.
    Fandriks L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol (oxf). 2011;201:157–67.CrossRefGoogle Scholar
  25. 25.
    Fandriks L. The angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst. 2010;11:43–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Hallersund P, Elfvin A, Helander HF, Fandriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst. 2011;12:54–64.CrossRefPubMedGoogle Scholar
  27. 27.
    Hallersund P, Helander HF, Casselbrant A, Edebo A, Fandriks L, Elfvin A. Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil. Bmc Gastroenterol. 2010;10:3.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Marietta EV, Nadeau AM, Cartee AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42:1303–14.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Esteve M, Temino R, Carrasco A, et al. Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Dig Liver Dis. 2016;48:154–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Ebrahim VS, Martin J, Murthy S, Odstrcil E, Huang H, Polter D. Olmesartan-associated enteropathy. Proc (bayl Univ Med Cent). 2017;30:348–50.CrossRefGoogle Scholar
  31. 31.
    Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Sun L, Wang W, Xiao W, Liang H, Yang Y, Yang H. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA‑6 and the Bax pathway. Biochem Biophys Res Commun. 2012;424:663–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Palmquist S, Mathews B. Isolated intestinal type angioedema due to ACE-inhibitor therapy. Clin Case Rep. 2017;5:707–10.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Locascio EJ, Mahler SA, Arnold TC. Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis. West J Emerg Med. 2010;11:391–4.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Talbot GH. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc. 2012;87:1231–2. author reply 2.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Cartee AK, Genere RJP, Oxentenko AS. New onset villous atrophy in a patient with celiac disease. Baillieres Clin Gastroenterol. 2018;155:988–9.Google Scholar
  37. 37.
    Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012;87:1230–1. author reply 2.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Theophile H, David XR, Miremont-Salame G, Haramburu F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014;46:465–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Eusebio M, Caldeira P, Antunes AG, et al. Olmesartan-induced Enteropathy: an unusual cause of villous atrophy. Ge Portuguese J Gastroenterol. 2016;23:91–5.CrossRefGoogle Scholar
  40. 40.
    Basson M, et al. Gut. 2015;0:1–6.Google Scholar
  41. 41.
    Ripellino C, Cataldo N, Scarpignato C. Unspecified intestinal malabsortion associated with angiotensin receptor blocker therapy (Abstract). Quintiles IMS, 2016, https://www.rwebibliography.com/print.php?&totalRows_Bibliographies=101&conditionid=7
  42. 42.
    Marild K, Lebwohl B, Green PH, Murray JA, Ludvigsson JF. Blockers of Angiotensin other than Olmesartan in patients with villous atrophy: a nationwide case-control study. Mayo Clin Proc. 2015;90:730–7.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Mondet L, Pierson-Marchandise, Gras V, Sevester H, Lawson P, Andrejak M, Masmoudi K. Angiotensin II receptor blcokers-induced enteropathy: not just olmesartan! A case report with candesartan. Fund Clin Pharmacol. 2016;30:67Google Scholar
  44. 44.
    Famularo G, Minisola G. Relapsing Olmesartan-Associated Ileitis. Ann Pharmacother. 2016;50:1070.CrossRefPubMedGoogle Scholar
  45. 45.
    van Gils T, Robijn RJ, Bouma G, Neefjes-Borst EA, Mulder CJJ. A pitfall in suspected (refractory) celiac disease: Losartan-induced Enteropathy. Am J Gastroenterol. 2017;112:1754–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Negro A, De Marco L, Cesario V, Santi R, Boni MC, Zanelli M. A case of moderate Sprue-like Enteropathy associated with Telmisartan. J Clin Med Res. 2017;9:1022–5.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Zanelli M, Negro A, Santi R, et al. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. Aliment Pharmacol Ther. 2017;46:471–3.CrossRefPubMedGoogle Scholar
  48. 48.
    Dong YH, Jin Y, Tsacogianis TN, He M, Hsieh PH, Gagne JJ. Use of olmesartan and enteropathy outcomes: a multi-database study. Aliment Pharmacol Ther. 2018;47:792–800.CrossRefPubMedGoogle Scholar
  49. 49.
    Greywoode R, Braunstein ED, Arguelles-Grande C, Green PH, Lebwohl B. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study. Mayo Clin Proc. 2014;89:1239–43.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Kamal A, Fain C, Park A, et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (oxf). 2019;7:162–7.CrossRefGoogle Scholar
  51. 51.
    Mondet I, Pierson-Marchandise M, Gras V, H. S, Lawsan P. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! Fundam Clin Pharmacol. 2016;30:47–62.Google Scholar
  52. 52.
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78.CrossRefPubMedGoogle Scholar
  54. 54.
    Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100:520–6.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):1.CrossRefGoogle Scholar
  56. 56.
    Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol Hepatol. 2009;24:1347–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Internal MedicineTauernkliniken GmbH
  2. 2.A.ö. Tauernkliniken—Zell am See & MittersillAkademisches Lehrkrankenhaus der Universitätskliniken Innsbruck, Graz, Wien und SalzburgZell am SeeAustria
  3. 3.Innere Medizin und Akutgeriatrie/Remobilisation, Krankenhaus OberndorfAkademisches Lehrkrankenhaus der Universitätskliniken Innsbruck, Graz, Wien und SalzburgOberndorfAustria

Personalised recommendations